| Year |
Citation |
Score |
| 2019 |
Rosenthal KS, Carambula R, Zimmerman DH. Why Don't We Have a Vaccine Against Autoimmune Diseases? - A Review. Journal of Clinical & Cellular Immunology. 10. PMID 31328022 DOI: 10.4172/2155-9899.1000574 |
0.341 |
|
| 2019 |
Zimmerman DH, Carambula RE, Ciemielewski J, Rosenthal KS. Lessons from next generation influenza vaccines for inflammatory disease therapies. International Immunopharmacology. 74: 105729. PMID 31280056 DOI: 10.1016/J.Intimp.2019.105729 |
0.362 |
|
| 2017 |
Mikecz K, Glant TT, Markovics A, Rosenthal KS, Kurko J, Carambula RE, Cress S, Steiner HL, Zimmerman DH. An epitope-specific DerG-PG70 LEAPS vaccine modulates T cell responses and suppresses arthritis progression in two related murine models of rheumatoid arthritis. Vaccine. PMID 28583308 DOI: 10.1016/J.Vaccine.2017.05.009 |
0.362 |
|
| 2017 |
Rosenthal KS, Stone S, Koski G, Zimmerman DH. LEAPS Vaccine Incorporating HER-2/neu Epitope Elicits Protection That Prevents and Limits Tumor Growth and Spread of Breast Cancer in a Mouse Model. Journal of Immunology Research. 2017: 3613505. PMID 28459074 DOI: 10.1155/2017/3613505 |
0.339 |
|
| 2015 |
Rosenthal KS, Mikecz K, Steiner HL, Glant TT, Finnegan A, Carambula RE, Zimmerman DH. Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis. Expert Review of Vaccines. 14: 891-908. PMID 25787143 DOI: 10.1586/14760584.2015.1026330 |
0.359 |
|
| 2015 |
Rosenthal KS, Sikon J, Kuntz A. Why don't we have a vaccine against.? Part 1. viruses Infectious Diseases in Clinical Practice. 23: 202-210. DOI: 10.1097/Ipc.0000000000000264 |
0.315 |
|
| 2012 |
Zimmerman DH, Steiner H, Carmabula R, Talor E, Rosenthal KS. LEAPS therapeutic vaccines as antigen specific suppressors of inflammation in infectious and autoimmune diseases. Journal of Vaccines & Vaccination. 3. PMID 23400692 DOI: 10.4172/2157-7560.1000149 |
0.418 |
|
| 2012 |
Rosenthal KS, Taylor P, Zimmerman DH. J-LEAPS peptide and LEAPS dendritic cell vaccines Microbial Biotechnology. 5: 203-213. PMID 21895992 DOI: 10.1111/J.1751-7915.2011.00278.X |
0.396 |
|
| 2010 |
Taylor PR, Koski GK, Paustian CC, Bailey E, Cohen PA, Moore FB, Zimmerman DH, Rosenthal KS. J-LEAPS vaccines initiate murine Th1 responses by activating dendritic cells. Vaccine. 28: 5533-42. PMID 20600501 DOI: 10.1016/J.Vaccine.2010.06.043 |
0.361 |
|
| 2010 |
Taylor PR, Paustian CC, Koski GK, Zimmerman DH, Rosenthal KS. Maturation of dendritic cell precursors into IL12-producing DCs by J-LEAPS immunogens. Cellular Immunology. 262: 1-5. PMID 20163792 DOI: 10.1016/J.Cellimm.2010.01.003 |
0.368 |
|
| 2010 |
Zimmerman DH, Taylor P, Bendele A, Carambula R, Duzant Y, Lowe V, O'Neill SP, Talor E, Rosenthal KS. CEL-2000: A therapeutic vaccine for rheumatoid arthritis arrests disease development and alters serum cytokine/chemokine patterns in the bovine collagen type II induced arthritis in the DBA mouse model. International Immunopharmacology. 10: 412-21. PMID 20074669 DOI: 10.1016/J.Intimp.2009.12.016 |
0.344 |
|
| 2010 |
Nazinitsky A, Rosenthal KS. Cytokine storms: Systemic disasters of infectious diseases Infectious Diseases in Clinical Practice. 18: 188-192. DOI: 10.1097/Ipc.0B013E3181D2Ee41 |
0.341 |
|
| 2010 |
Taylor P, Koski G, Bailey E, Zimmerman D, Rosenthal KS. J-LEAPS Vaccines Mature Mouse Bone Marrow Cells to Dendritic Cells-1 (DC1) which can Deliver Protective Immunity Clinical Immunology. 135: S32. DOI: 10.1016/J.Clim.2010.03.098 |
0.318 |
|
| 2009 |
Chatterjee S, Wang JW, Cismowski MJ, Bower JR, Rosenthal KS. HSV-2 ICP34.5 protein modulates herpes simplex virus glycoprotein processing. Archives of Virology. 154: 661-3. PMID 19267180 DOI: 10.1007/S00705-009-0341-9 |
0.579 |
|
| 2009 |
Brammer J, Rosenthal KS. Oncolytic viruses: Therapeutic smart bombs Infectious Diseases in Clinical Practice. 17: 39-43. DOI: 10.1097/Ipc.0B013E31818D1B02 |
0.357 |
|
| 2007 |
Patel SS, Rosenthal KS. Microbial adaptation: Putting the best team on the field Infectious Diseases in Clinical Practice. 15: 330-334. DOI: 10.1097/Ipc.0B013E31814B1B47 |
0.321 |
|
| 2006 |
Rosenthal KS. Viruses: Microbial spies and saboteurs Infectious Diseases in Clinical Practice. 14: 97-106. DOI: 10.1097/01.Idc.0000216924.02922.Ad |
0.38 |
|
| 2006 |
Rosenthal KS. Vaccines make good immune theater: Immunization as described in a three-act play Infectious Diseases in Clinical Practice. 14: 35-45. DOI: 10.1097/01.Idc.0000201779.55618.1B |
0.373 |
|
| 2005 |
Rosenthal KS. Immune peptide enhancement of peptide based vaccines Frontiers in Bioscience. 10: 478-482. PMID 15574384 DOI: 10.2741/1543 |
0.341 |
|
| 2005 |
Goel N, Zimmerman DH, Rosenthal KS. Ligand epitope antigen presentation system vaccines against herpes simplex virus. Frontiers in Bioscience : a Journal and Virtual Library. 10: 966-74. PMID 15569635 DOI: 10.2741/1591 |
0.405 |
|
| 2005 |
Zimmerman DH, Rosenthal KS. The L.E.A.P.S. approach to vaccine development Frontiers in Bioscience : a Journal and Virtual Library. 10: 790-798. PMID 15569618 DOI: 10.2741/1572 |
0.371 |
|
| 2004 |
Charoenvit Y, Goel N, Whelan M, Rosenthal KS, Zimmerman DH. CEL-1000--a peptide with adjuvant activity for Th1 immune responses. Vaccine. 22: 2368-73. PMID 15193396 DOI: 10.1016/J.Vaccine.2003.11.062 |
0.318 |
|
| 2003 |
Goel N, Rong Q, Zimmerman D, Rosenthal KS. A L.E.A.P.S.™ heteroconjugate vaccine containing a T cell epitope from HSV-1 glycoprotein D elicits Th1 responses and protection Vaccine. 21: 4410-4420. PMID 14505924 DOI: 10.1016/S0264-410X(03)00429-8 |
0.407 |
|
| 2003 |
Mao H, Rosenthal KS. Strain-dependent structural variants of herpes simplex virus type 1 ICP34.5 determine viral plaque size, efficiency of glycoprotein processing, and viral release and neuroinvasive disease potential. Journal of Virology. 77: 3409-17. PMID 12610116 DOI: 10.1128/Jvi.77.6.3409-3417.2003 |
0.607 |
|
| 2003 |
Rong Q, Alexander TS, Koski GK, Rosenthal KS. Multiple mechanisms for HSV-1 induction of interferon α production by peripheral blood mononuclear cells Archives of Virology. 148: 329-344. PMID 12556996 DOI: 10.1007/S00705-002-0912-5 |
0.406 |
|
| 2002 |
Goel N, Mao H, Rong Q, Docherty JJ, Zimmerman D, Rosenthal KS. The ability of an HSV strain to initiate zosteriform spread correlates with its neuroinvasive disease potential. Archives of Virology. 147: 763-73. PMID 12038686 DOI: 10.1007/S007050200024 |
0.546 |
|
| 2002 |
Mao H, Rosenthal KS. An N-terminal arginine-rich cluster and a proline-alanine-threonine repeat region determine the cellular localization of the herpes simplex virus type 1 ICP34.5 protein and its ligand, protein phosphatase 1. The Journal of Biological Chemistry. 277: 11423-31. PMID 11788604 DOI: 10.1074/Jbc.M111553200 |
0.577 |
|
| 2001 |
Mao H, Palmer D, Rosenthal KS. Changes in BiP (GRP78) levels upon HSV-1 infection are strain dependent. Virus Research. 76: 127-35. PMID 11410313 DOI: 10.1016/S0168-1702(01)00257-X |
0.58 |
|
| 1999 |
Mao H, Rosenthal KS. Synthesis of radioactive single-stranded DNA probes using asymmetrical PCR and oligonucleotide random priming. Biotechniques. 27: 674-6, 678. PMID 10524303 DOI: 10.2144/99274Bm08 |
0.477 |
|
| 1999 |
Bower JR, Mao H, Durishin C, Rozenbom E, Detwiler M, Rempinski D, Karban TL, Rosenthal KS. Intrastrain variants of herpes simplex virus type 1 isolated from a neonate with fatal disseminated infection differ in the ICP34.5 gene, glycoprotein processing, and neuroinvasiveness. Journal of Virology. 73: 3843-53. PMID 10196279 DOI: 10.1128/Jvi.73.5.3843-3853.1999 |
0.584 |
|
| 1999 |
Rosenthal KS, Mao H, Horne WI, Wright C, Zimmerman D. Immunization with a LEAPS heteroconjugate containing a CTL epitope and a peptide from beta-2-microglobulin elicits a protective and DTH response to herpes simplex virus type 1. Vaccine. 17: 535-42. PMID 10075159 DOI: 10.1016/S0264-410X(98)00231-X |
0.575 |
|
| 1997 |
Walro DG, Rosenthal KS. The antiviral xanthate compound D609 inhibits herpes simplex virus type 1 replication and protein phosphorylation Antiviral Research. 36: 63-72. PMID 9330762 DOI: 10.1016/S0166-3542(97)00040-5 |
0.338 |
|
| 1995 |
Dick JW, Rosenthal KS. A block in glycoprotein processing correlates with small plaque morphology and virion targetting to cell-cell junctions for an oral and an anal strain of herpes simplex virus type-1 Archives of Virology. 140: 2163-2181. PMID 8572939 DOI: 10.1007/Bf01323238 |
0.419 |
|
| 1989 |
Rosenthal KS, Killius J, Hodnichak CM, Venetta TM, Gyurgyik L, Janiga K. Mild acidic pH inhibition of the major pathway of herpes simplex virus entry into HEp-2 cells Journal of General Virology. 70: 857-867. PMID 2543762 DOI: 10.1099/0022-1317-70-4-857 |
0.349 |
|
| 1988 |
Rosenthal KS, Roess D, Barisas BG. Herpes simplex virus type 1 penetration initiates mobilization of cell surface proteins. Biochimica Et Biophysica Acta. 942: 38-44. PMID 2838084 DOI: 10.1016/0005-2736(88)90272-6 |
0.387 |
|
| 1986 |
Mohanty JG, Rosenthal KS. 2-Deoxy-d-glucose inhibition of herpes simplex virus type-1 receptor expression Antiviral Research. 6: 137-149. PMID 3015018 DOI: 10.1016/0166-3542(86)90008-2 |
0.342 |
|
| 1985 |
Mohanty JG, Rosenthal KS. A micropreparation of fluorescein conjugates of immunoglobulin G and fab from serum Analytical Biochemistry. 146: 361-365. PMID 3927771 DOI: 10.1016/0003-2697(85)90552-4 |
0.324 |
|
| 1985 |
Rosenthal KS, Perez R, Hodnichak C. Inhibition of herpes simplex virus type 1 penetration by cytochalasins B and D Journal of General Virology. 66: 1601-1605. PMID 2991432 DOI: 10.1099/0022-1317-66-7-1601 |
0.37 |
|
| 1984 |
Hodnichak CM, Turley-Shoger E, Mohanty JG, Rosenthal KS. Visualization of herpes simplex virus type 1 attachment to target cells using staphylococcus aureus as a morphologic tag Journal of Virological Methods. 8: 191-198. PMID 6086689 DOI: 10.1016/0166-0934(84)90013-2 |
0.379 |
|
| Show low-probability matches. |